Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SPR | P35270 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884859 | 1.00 | SETD7 (0.49) | SETD7NR1H2HSD17B10MAP4K4EPHX2 | |
| SCHEMBL4681133 | 1.00 | SETD7 (0.49) | SETD7NR1H2HSD17B10MAP4K4EPHX2 | |
| SCHEMBL4336794 | 0.89 | SETD7 (0.52) | SETD7NR1H2MAP4K4EPHX2SPR | |
| SCHEMBL16016742 | 0.88 | SETD7 (0.49) | SETD7NR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL21806131 | 0.88 | SETD7 (0.49) | SETD7NR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL4681348 | 0.88 | SETD7 (0.49) | SETD7NR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL2053722 | 0.86 | SETD7 (0.50) | SETD7NR1H2HSD17B10MAP4K4SPR | |
| SCHEMBL31094813 | 0.86 | SETD7 (0.50) | SETD7NR1H2HSD17B10MAP4K4SPR | |
| SCHEMBL15105056 | 0.86 | SETD7 (0.50) | SETD7NR1H2HSD17B10MAP4K4SPR | |
| SCHEMBL3639918 | 0.86 | SETD7 (0.50) | SETD7NR1H2HSD17B10MAP4K4SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115322158-B | As KRASG12CSubstituted quinazoline compounds of protein inhibitor | 江南大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-112996784-B | Indole derivatives and their use in medicine | 北京越之康泰生物医药科技有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-115322158-A | As KRAS G12C Substituted quinazoline compounds of protein inhibitor | 江南大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-112996784-A | Indole derivatives and their use in medicine | 北京越之康泰生物医药科技有限公司 | 2021-06-18 | — | — | CN | disclosed |
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| US-7022707-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040235859-A1 | Novel piperazine derivatives | ADAMS DAVID REGINALD (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235859-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | SETD7 208/4885NR1H2 1100/4885HSD17B10 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.